Zhang Ning, Professor, 973 chief scientist, winner of the national "ten thousand talents plan",
winner of the National Science Fund for Distinguished Young Scholars, young and middle-aged leading
talents for scientific and technological innovation of the Ministry of science and technology, millions
of talents of the Ministry of personnel, outstanding contribution expert, new century outstanding talents
of the Ministry of education, and winner of the outstanding achievement award of the Lee Foundation of the
United States; Executive deputy director of cancer transformation research center of the first hospital of
Peking University; Executive director and Deputy Secretary General of China Anti Cancer Association,
chairman of periodical publishing professional committee of China Anti Cancer Association, and former chairman
of nano oncology professional committee; Chairman of the translational medicine sub committee of the
Chinese gerontology and Geriatrics Association; Executive deputy editor of cancer biology & Medicine, deputy
editor of medical review.Professor Zhang Ning has been engaged in biomedical research for a long time.
Focusing on the key clinical problem of liver cancer, he has carried out transformation application
research from the aspects of molecular genetics, cell biology, drug screening, nanotechnology and so on,
and has achieved a series of scientific research achievements. In the past five years, Professor Zhang Ning
has published more than 100 articles in science, cancer cell, Gastroenterology, Hepatology, ACS Nano, genome
research, nature communication, PNAs and other academic journals, and has been cited more than 6000 times in
total, winning the 2019 China annual paper of cell press. At the same time, Professor Zhang Ning's research work
has been supported by a number of funds, such as the National Fund Commission and the Ministry of science and technology.
Research on molecular typing of tumor precise drug sensitivity and clinical transformation:
At present, the team has established a large-scale high-quality organoid biobank for the first time through
multi-point sampling of liver cancer surgical specimens from nearly 100 patients. The biobank can better
preserve the heterogeneity of liver cancer patients, and can be used for large-scale drug screening and molecular
typing. At present, the team has revealed the molecular typing of drug sensitivity of clinical medication for
liver cancer and the feasibility of proposing a combined medication scheme, which provides a certain basis and
clues for the precise clinical diagnosis and treatment of liver cancer.
Exploration and Research on precise diagnosis and treatment guided by tumor immune microenvironment:
Immunotherapy can significantly improve the survival rate of patients with advanced cancer and become a
breakthrough in the field of cancer treatment, but it is only effective for some patients at present.
How to screen patients suitable for immunotherapy and how to improve the efficacy of ineffective patients
are the key technical bottlenecks in this field. In order to solve the problem of precise immunotherapy
for advanced liver cancer, the team closely combined with the characteristics of liver cancer in China,
through the construction of sample banks of different subtypes of liver cancer tissues, and single-cell
sequencing analysis, in-depth study of the typing and composition proportion of various cells in the immune
microenvironment, found that each cancer has different immune microenvironment cell subsets, which are highly
correlated with the prognosis of liver cancer patients after immunotherapy, It has been verified in animal
experiments. On this basis, we are developing new methods for the diagnosis and treatment of liver cancer specific
immune cell subsets, including in vitro diagnostic kits, radioactive diagnostic drugs, chemotherapy and targeted
therapeutic drugs, in order to achieve accurate diagnosis and treatment of liver cancer patients.
